Ono Pharmaceutical Reports Promising Phase 2 Results for ONO-2808 in Multiple System Atrophy Treatment
核心洞察
Ono Pharmaceutical announced encouraging efficacy signals for ONO-2808, a selective S1P5 receptor agonist, in an interim analysis of a Phase 2 clinical trial for multiple system atrophy patients.
The study showed that disease progression tended to be slower in the ONO-2808 group compared to placebo, as measured by the Unified Multiple System Atrophy Rating Scale.
All doses were well tolerated with a manageable safety profile, offering hope for the first disease-modifying treatment for this rare neurodegenerative condition.
Ono PharmaceuticalSearch company Co., Ltd. announced encouraging efficacy signals for ONO-2808Search drug, a selective sphingosine 1-phosphate (S1P5) receptor agonist, in an interim analysis of its Phase 2 clinical trial for multiple system atrophySearch disease (MSASearch disease). The exploratory analysis revealed that disease progression tended to be slower in patients receiving ONO-2808 compared to placebo, as measured by the Unified Multiple System Atrophy Rating Scale (UMSARS). All doses demonstrated good tolerability with a manageable safety profile.
Clinical Trial Design and Results
The ONO-2808Search drug-03 study is a multicenter, randomized Phase 2 clinical trial conducted in early MSASearch disease patients within 5 years of symptom onset across Japan and the United States. The two-part study design includes a core phase where participants received ONO-2808 at three different doses or placebo orally once daily for 24 weeks. The primary objectives of the core part focus on assessing safety, tolerability, pharmacokinetics, and potential efficacy compared to placebo.
Following completion of the core phase, an extension part will administer ONO-2808Search drug for up to 80 weeks to evaluate the safety, tolerability, and potential efficacy of long-term treatment. Ono plans to present the detailed results at an upcoming medical and scientific conference.
Addressing Critical Unmet Medical Need
Multiple system atrophySearch disease represents a progressive neurodegenerative disease characterized by gradual neuronal loss in the brain due to abnormal accumulation of α-synucleinSearch term protein. The condition manifests through multiple symptom categories including Parkinson's-like symptoms such as muscle stiffness, cerebellar ataxia including difficulty walking, and autonomic dysfunction encompassing orthostatic dizziness and urinary incontinence.
The disease carries a particularly poor prognosis, with an average life expectancy of 9 to 10 years. Approximately 80% of patients require walking assistance within 5 years of onset, and only 20% survive for at least 12 years. In Japan, MSASearch disease has been designated as an intractable disease, affecting an estimated 10,000 patients as of the end of fiscal year 2019. The United States patient population is estimated between 15,000 to 50,000, with some estimates suggesting approximately 40,000 affected individuals.
Currently, no approved disease-modifying treatments exist for MSASearch disease, with standard care limited to symptomatic treatment and rehabilitation approaches.
Novel Mechanism of Action
ONO-2808Search drug represents an orally bioavailable selective agonist targeting the S1P5 receptorSearch term, one of the sphingosine 1-phosphate receptors discovered by Ono. S1P5 receptors play crucial roles in maintaining normal nerve function, particularly in stabilizing and regenerating the myelin sheath covering nerve axons. This process occurs through promoting differentiation of oligodendrocytes, specialized glial cells present in the central nervous system including the brain and spinal cord.
The selective S1P5 receptorSearch term agonist is expected to alleviate MSASearch disease progression through two primary mechanisms: promoting remyelination and inhibiting α-synucleinSearch term accumulation in the central nervous system, which represents the underlying cause of MSA pathology.
Potential First-in-Class Treatment
If successful in later-stage development, ONO-2808Search drug could become the first-in-class treatment specifically targeting the disease-modifying mechanisms underlying multiple system atrophySearch disease. The encouraging interim results represent a significant development for patients facing this aggressive neurodegenerative condition with limited therapeutic options.